Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Paediatric HIV slow-progression is associated with early CD8+ T-cell PD-1 expression and a stem-like phenotype.

Adriano Vieira V. et al, (2023), JCI Insight

Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion.

Jay C. et al, (2023), Front Immunol, 14

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.

Huo J. et al, (2022), Cell Rep

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.

Fidler S. et al, (2022), Clin Infect Dis

Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope.

Dolton G. et al, (2022), Cell, 185, 2936 - 2951.e19

Next-generation point-of-care testing in pediatric human immunodeficiency virus infection facilitates diagnosis and monitoring of treatment

Bengu N. et al, (2022), Medicine (United States), 101

Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence.

Fernández-Luis S. et al, (2022), BMC Public Health, 22

Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV)

Khan K. et al, (2022), Clinical Infectious Diseases, 75, E857 - E864

Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and with Human Immunodeficiency Virus on Antiretroviral Therapy during the First South African Infection Wave

Snyman J. et al, (2022), Clinical Infectious Diseases, 75, E249 - E256

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Tuekprakhon A. et al, (2022), Cell

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.

Nutalai R. et al, (2022), Cell

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), JCI Insight, 7

A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.

Sampson O. et al, (2022), J Immunol Methods, 504

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A. et al, (2022), Nat Commun, 13

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.

Zacharopoulou P. et al, (2022), Sci Rep, 12

Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy.

Ruggiero A. et al, (2022), Front Immunol, 13

HIV specific CD8+ TRM-like cells in tonsils express exhaustive signatures in the absence of natural HIV control.

Fardoos R. et al, (2022), Front Immunol, 13

Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era.

Vieira VA. et al, (2022), Front Immunol, 13

Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts.

Brown R. et al, (2022), Wellcome Open Res, 7

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Angyal A. et al, (2022), The Lancet Microbe, 3, e21 - e31

Load More

1
2
3
4
5
6
7
...
»